Psilocybin Reduces Symptoms, Disability in Major Depression

Phase 2 data suggest significant sustained benefits with an experimental psilocybin drug in the treatment of major depressive disorder.

Related Keywords

United States , Wisconsin , Maryland , New York , American , Caleb Alexander , Williama Linton , Rachel Yehuda , Amy Lehrner , Drug Administration , Fournier Family Foundation , Multidisciplinary Association For Psychedelic Studies Public Benefit , Journal Of The American Medical Association , Johns Hopkins University In Baltimore , Turnbull Family Foundation , Usona Institute , Alexandra Cohen Foundation , Novartis , Icahn School Of Medicine At Mount Sinai , Tiny Blue Dot Foundation , Vail Health , Peters Va Medical Center , Usona Institute Raison , Charles Raison , Medscape Medical News , American Medical , Depression Rating Scale , Sheehan Disability Scale , Drug Safety , Johns Hopkins University , Medscape Medical , Icahn School , Mount Sinai , Good Ventures , Emory Healthcare , Multidisciplinary Association , Psychedelic Studies Public Benefit , Major Depression , Major Depressive Disorder , Nipolar Depression , Depression , Psychotropic , Psychoactive , Hallucinogens , Disability , Niacin , Nicotinic Acid , Vitamin B3 , Itamin Pp , Nausea , Headache , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Patient Safety , Adverse Effects , Side Effects , Antidepressant , Antidepressant Drug , Rug Antidepres ,